Evaluation of Hematologic Parameters in Patients with COVID-19 Following Mesenchymal Stem Cell Therapy.
Haniye BakhshiMasoud SoleimaniMina SoufizomorrodOmid KooshkakiPublished in: DNA and cell biology (2022)
At present, severe acute respiratory syndrome coronavirus 2 is spreading and has caused over 188 million confirmed patients and more than 4,059,101 deaths. Currently, several clinical trials are done using mesenchymal stem cell (MSC) therapy in patients with coronavirus disease 2019 (COVID-19). These cells have shown safety and effectiveness, implying a promising clinical application in patients with COVID-19. Studies have shown that abnormalities in hematological measures such as white blood cells count, neutrophilia, elevated neutrophil to lymphocyte ratio, inflammatory markers, and lactate dehydrogenase can be used to assess the severity of COVID-19 disease and the response to therapy following MSC treatment. Our study has aimed to review the role of hematological factors in determination of responsiveness to MSC therapy and disease severity in COVID-19 patients.
Keyphrases
- coronavirus disease
- respiratory syndrome coronavirus
- sars cov
- clinical trial
- mesenchymal stem cells
- induced apoptosis
- end stage renal disease
- bone marrow
- systematic review
- randomized controlled trial
- chronic kidney disease
- cell therapy
- ejection fraction
- newly diagnosed
- replacement therapy
- cell death
- solid phase extraction